Pheochromocytoma Clinical Trial
— MICROBATOfficial title:
Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue: Proof of Concept Against PET-CT in Patients Affected by Pheochomocytoma and/or Paraganglioma
Verified date | May 2024 |
Source | University of Avignon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients affected by pheochromocytoma (PHEO) have brown-adipose tissue (BAT) hyperactivation. They perform, in routine settings, a FDG PET-CT scan. The high metabolic activity of BAT and its ability to consume both glucose and fatty acid suggest that it may have potential as a therapeutic target in the treatment of obesity. However, alternative non-invasive techniques to PET-CT BAT detection still need more validation. Accordingly, our aim will be to measure the temperature and microcirculation of the skin overlaying BAT depots in the region of FDG-uptake detected by 18F-FDG PET/CT before and after a cold test in PHEO patients.
Status | Terminated |
Enrollment | 7 |
Est. completion date | October 20, 2023 |
Est. primary completion date | April 29, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients with confirmed pheochromocytoma and/or paraganglioma Exclusion Criteria: - pregnant woman - breastfeeding woman |
Country | Name | City | State |
---|---|---|---|
France | Pôle ENDO- Hopital la Conception APHM | Marseille | Paca |
Lead Sponsor | Collaborator |
---|---|
University of Avignon | Assistance Publique Hopitaux De Marseille, Centre Hospitalier Henri Duffaut - Avignon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Skin temperature in supra-clavicular region in basal condition (TSCRbasal) | Skin temperature in supra-clavicular region will be recorded by infrared thermography (FLIR camera) in basal condition | Day 0 | |
Primary | Skin temperature in supra-clavicular region during a cold test (TSCRcold) | Skin temperature in supra-clavicular region will be recorded by infrared thermography (FLIR camera) during a cold test (feet in water at 19°C during 20min) | Day 0 | |
Primary | Baseline difference in skin temperature in supra-clavicular region (diff TSCR) | diff TSCR (day 0) = TSCRcold - TSCRbasal | Day 0 | |
Secondary | Cutaneous blood flow in supra-clavicular region in basal condition (PUbasal) | Cutaneous blood flow in supra-clavicular region will be recorded by Laser Speckle Imaging (PeriCam) in basal condition | Day 0 | |
Secondary | Cutaneous blood flow in supra-clavicular region during a cold test (PUcold) | Cutaneous blood flow in supra-clavicular region will be recorded by Laser Speckle Imaging (PeriCam) during a cold test (feet in water at 19°C during 20min) | Day 0 | |
Secondary | Baseline difference in cutaneous blood flow in supra-clavicular region (?PU) | diff PU (day0) =PUcold-PUbasal | Day 0 | |
Secondary | Volume of Brown Adipose Tissue detected by PET-CT | 18FDG PET-CT will be performed and volume will be segmented by PET/CT Viewer.. | Day 0 | |
Secondary | Activity of Brown Adipose Tissue detected by PET-CT | 18FDG PET-CT will be performed and BAT activity (Standardized Uptake Value (SUV) will be segmented by PET/CT Viewer.. | Day 0 | |
Secondary | Change from baseline difference in skin temperature in supra-clavicular region ( ? diffTSCR) at 12 months | ? diff TSCR = diff TSCR(month12) - diff TSCR (day0) | Month 12 | |
Secondary | Change from baseline difference in cutaneous blood flow in supra-clavicular region ( ? diff PU) at 12 months | ? diff PU = diff PU (month12) - diff PU (day0) | Month 12 | |
Secondary | Volume of Brown Adipose Tissue detected by PET-CT | 18FDG PET-CT will be performed and volume will be segmented by PET/CT Viewer.. | Month 12 | |
Secondary | Activity of Brown Adipose Tissue detected by PET-CT | 18FDG PET-CT will be performed and BAT activity (Standardized Uptake Value (SUV) will be segmented by PET/CT Viewer.. | Month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06050057 -
Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
|
||
Recruiting |
NCT05636618 -
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03986593 -
Cryoablation of Bone Metastases From Endocrine Tumors
|
N/A | |
Terminated |
NCT05948137 -
F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma
|
||
Completed |
NCT00970970 -
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
|
||
Active, not recruiting |
NCT00436735 -
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00669266 -
Adrenal Tumors - Pathogenesis and Therapy
|
||
Recruiting |
NCT05069220 -
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
|
Early Phase 1 | |
Recruiting |
NCT06062082 -
Intraoperative Hemodynamic Instability During Unilateral Adrenalectomy for Pheochromocytoma
|
||
Recruiting |
NCT04573816 -
Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma
|
||
Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
Not yet recruiting |
NCT06045260 -
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
|
Phase 2 | |
Completed |
NCT00001147 -
Blood Sampling for Neurochemical and Genetic Testing
|
N/A | |
Terminated |
NCT00002947 -
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
|
Phase 1 | |
Completed |
NCT00001229 -
Diagnosis and Treatment of Pheochromocytoma
|
N/A | |
Completed |
NCT01967576 -
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
|
Phase 2 | |
Recruiting |
NCT03160274 -
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
|
||
Recruiting |
NCT03206060 -
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
|
Phase 2 | |
Not yet recruiting |
NCT04788927 -
Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
|
||
Enrolling by invitation |
NCT03474237 -
A Prospective Cohort Study for Patients With Adrenal Diseases
|